Article Text

PDF
Changes in circulating mesenchymal stem cells, stem cell homing factor, and vascular growth factors in patients with acute ST elevation myocardial infarction treated with primary percutaneous coronary intervention
  1. Y Wang1,
  2. H E Johnsen2,
  3. S Mortensen2,
  4. L Bindslev2,
  5. R Sejersten Ripa1,
  6. M Haack-Sørensen2,
  7. E Jørgensen1,
  8. W Fang3,
  9. J Kastrup1
  1. 1Medical Department B, Cardiac Catheterisation Laboratory, The Heart Centre, University Hospital, Rigshospitalet, Copenhagen, Denmark
  2. 2Department of Haematology, Herlev University Hospital, Herlev, Denmark
  3. 3Department of Cardiology, Shanghai Chest Hospital, Shanghai, China
  1. Correspondence to:
    Dr Jens Kastrup
    Medical Department B, Cardiac Catheterisation Laboratory 2014, The Heart Centre, University Hospital Rigshospitalet, DK-2100 Copenhagen Ø, Denmark; jkastrup{at}rh.dk

Abstract

Objective: To investigate the spontaneous occurrence of circulating mesenchymal stem cells (MSC) and angiogenic factors in patients with ST elevation acute myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).

Design: In 20 patients with STEMI, blood samples were obtained on days 1, 3, 7, 14, 21, and 28 after the acute PCI. Fifteen patients with a normal coronary angiography formed a control group. MSC (CD45−/CD34−), plasma stromal derived factor 1 (SDF-1), vascular endothelial growth factor A (VEGF-A), and fibroblast growth factor 2 (FGF-2) were measured by multiparametric flow cytometry and enzyme linked immunosorbent assay (ELISA).

Results: Circulating CD45−/CD34− cells were significantly decreased on day 7 compared with day 3. Cell counts normalised one month after the acute onset of STEMI. The changes were mainly seen in patients with a large infarction. Plasma SDF-1 increased significantly from day 3 to day 28, and VEGF-A and FGF-2 increased significantly from day 7 to day 28.

Conclusions: Spontaneous sequential fluctuations in MSC and the increase in vascular growth factor concentrations after STEMI suggest that the optimal time for additional stem cell therapy is three weeks after a myocardial infarction to obtain the maximum effects by stimulating endogenous growth factors on the delivered stem cells.

  • CK, creatine kinase
  • CXCR-4, CXC chemokine receptor 4
  • ELISA, enzyme linked immunosorbent assay
  • FGF-2, fibroblast growth factor 2
  • MSC, mesenchymal stem cells
  • PCI, percutaneous coronary intervention
  • PECAM-1, platelet endothelial cell adhesion molecule 1
  • SDF-1, stromal derived factor 1
  • STEMI, ST elevation acute myocardial infarction
  • TIMI, thrombolysis in myocardial infarction
  • VEGF, vascular endothelial growth factor
  • stem cell
  • cytokines
  • angiogenesis
  • vasculogenesis
  • acute myocardial infarction

Statistics from Altmetric.com

Footnotes

  • Published Online First 26 October 2005

  • Conflict of interest: Nothing declared.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.